<!DOCTYPE html>
<html lang="zh-CN">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>ğŸ§¬ PubMed RNA Editing Daily Digest</title>
  <style>
    body {
      font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', system-ui, sans-serif;
      background: #050816;
      color: #e5e7eb;
      margin: 0;
      padding: 1.5rem;
      max-width: 900px;
      margin-inline: auto;
    }
    header {
      margin-bottom: 2rem;
      border-bottom: 1px solid #1f2937;
      padding-bottom: 1.5rem;
    }
    h1 {
      margin: 0 0 .5rem;
      font-size: 1.9rem;
    }
    .desc {
      color: #9ca3af;
      font-size: .95rem;
    }
    .date {
      margin-top: .75rem;
      color: #a5b4fc;
      font-weight: 500;
    }
    .count {
      font-size: .9rem;
      color: #9ca3af;
      margin-top: .25rem;
    }
    .archive-top {
      margin-top: .5rem;
      font-size: .9rem;
    }
    .archive-top a {
      color: #a5b4fc;
      text-decoration: none;
    }
    .paper-card {
      background: #020617;
      border-radius: .75rem;
      border: 1px solid #1f2937;
      padding: 1.25rem 1.4rem;
      margin-bottom: 1rem;
    }
    .paper-header {
      display: flex;
      justify-content: space-between;
      align-items: center;
      margin-bottom: .4rem;
      font-size: .8rem;
      color: #9ca3af;
      gap: .75rem;
    }
    .paper-header .left {
      display: flex;
      align-items: center;
      gap: .5rem;
    }
    .journal {
      text-transform: uppercase;
      letter-spacing: .08em;
    }
    .date {
      font-variant-numeric: tabular-nums;
    }
    .score-badge {
      border-radius: 999px;
      border: 1px solid #4f46e5;
      padding: 0.15rem 0.6rem;
      font-size: 0.78rem;
      color: #a5b4fc;
      background: rgba(79, 70, 229, 0.12);
    }
    .title {
      margin: .2rem 0 .4rem;
      font-size: 1.05rem;
      line-height: 1.4;
    }
    .title a {
      color: #e5e7eb;
      text-decoration: none;
    }
    .title a:hover {
      color: #a5b4fc;
    }
    .title-zh {
      margin: 0 0 .4rem;
      color: #9ca3af;
      font-size: .92rem;
    }
    .authors {
      margin: 0 0 .7rem;
      color: #9ca3af;
      font-size: .85rem;
    }
    .summary {
      background: #020617;
      border-radius: .5rem;
      border: 1px solid #1f2937;
      padding: .7rem .8rem;
      font-size: .86rem;
      margin-bottom: .5rem;
    }
    .summary-block {
      margin-bottom: .35rem;
    }
    .summary-block:last-child {
      margin-bottom: 0;
    }
    .summary-block strong {
      color: #a5b4fc;
      margin-right: .25rem;
    }
    details.abstract {
      margin-top: .3rem;
      font-size: .85rem;
    }
    details.abstract summary {
      cursor: pointer;
      color: #9ca3af;
    }
    details.abstract p {
      margin-top: .4rem;
      color: #9ca3af;
    }
    footer {
      margin-top: 2rem;
      padding-top: 1.5rem;
      border-top: 1px solid #1f2937;
      font-size: .8rem;
      color: #6b7280;
    }
    footer a {
      color: #a5b4fc;
      text-decoration: none;
    }
  </style>
</head>
<body>
  <header>
    <h1>ğŸ§¬ PubMed RNA Editing Daily Digest</h1>
    <p class="desc">æœ€è¿‘ 30 å¤©å†…å¯ç¼–ç¨‹ RNA ç¼–è¾‘ / gRNA å·¥ç¨‹å·¥å…·ç›¸å…³è®ºæ–‡ç²¾é€‰</p>
    <div class="date">ğŸ“… 2026-02-28</div>
    <div class="count">å…± 5 ç¯‡ç²¾é€‰è®ºæ–‡</div>
    <div class="archive-top"><a href="archive.html">æŸ¥çœ‹å†å²å½’æ¡£ â†’</a></div>
  </header>

  <main>
  <article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">International journal of molecular sciences</span>
      <span class="date">2026-02-14</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 85/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/41751993/" target="_blank">Evolution of Engineered ADAR-Based RNA Editing Systems.</a>
  </h3>
  <p class="title-zh">å·¥ç¨‹åŒ–ADAR RNAç¼–è¾‘ç³»ç»Ÿçš„æ¼”è¿›</p>
  <p class="authors">Borkiewicz L</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> åŸºäºADARçš„RNAç¢±åŸºç¼–è¾‘å™¨ï¼ˆå¯ç¼–ç¨‹RNAç¼–è¾‘å¹³å°ï¼‰</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> è¯¥ç»¼è¿°æ€»ç»“äº†ADARç¼–è¾‘ç³»ç»Ÿçš„æ ¸å¿ƒè®¾è®¡æ¼”è¿›æ€è·¯ï¼š1ï¼‰ä»ä½¿ç”¨åä¹‰å¯¡æ ¸è‹·é…¸ä½œä¸ºå‘å¯¼RNAæ‹›å‹Ÿå†…æºæ€§æˆ–è¿‡è¡¨è¾¾çš„ADARé…¶ï¼Œåˆ°2ï¼‰è®¾è®¡æ›´å¤æ‚çš„ç³»ç»Ÿï¼Œé¢å¤–è¡¨è¾¾å…¶ä»–RNAç»“åˆè›‹ç™½ä»¥å¢å¼ºæ‹›å‹Ÿå’Œç‰¹å¼‚æ€§ï¼Œå†åˆ°3ï¼‰é€šè¿‡ç†æ€§è®¾è®¡æ”¹é€ ADARé…¶ä»¥è½¬æ¢å…¶ä»–æ ¸è‹·é…¸å¹¶æ”¾å¤§åˆå§‹ç¼–è¾‘ä¿¡å·ã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. å®ç°ä½ç‚¹ç‰¹å¼‚æ€§çš„A-to-Iï¼ˆè¯»ä½œGï¼‰RNAç¼–è¾‘ï¼Œä»¥ä¿®å¤è‡´ç—…æ€§ç‚¹çªå˜ã€‚
2. é€šè¿‡ç¼–è¾‘mRNAï¼Œå®ç°éåŒä¹‰å¯†ç å­æ”¹å˜ï¼Œä»è€Œè°ƒæ§è›‹ç™½è´¨åŠŸèƒ½ã€‚
3. ä½œä¸ºç ”ç©¶å·¥å…·ï¼Œç”¨äºæ¢ç´¢RNAç¼–è¾‘çš„ç”Ÿç‰©å­¦åŠŸèƒ½ã€‚
4. ä½œä¸ºæ½œåœ¨çš„æ²»ç–—å¹³å°ï¼Œç”¨äºçº æ­£ç”±G-to-Açªå˜ç­‰å¼•èµ·çš„é—ä¼ ç–¾ç—…ã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> æœ¬æ–‡æ˜¯ä¸€ç¯‡ç»¼è¿°ï¼ŒæœªæŠ¥å‘Šå…·ä½“çš„å®éªŒæ•°æ®ã€‚æ–‡ç« æ€»ç»“äº†è¯¥é¢†åŸŸçš„å…³é”®æ€§èƒ½æŒ‘æˆ˜ä¸ç›®æ ‡ï¼šæé«˜ç¼–è¾‘çš„ç‰¹å¼‚æ€§å’Œæ•ˆç‡ã€å¢åŠ å¯é¶å‘ä½ç‚¹æ•°é‡ã€å‡å°‘è„±é¶å’Œæ—è§‚è€…ç¼–è¾‘æ´»æ€§ï¼Œä»¥åŠåœ¨å¹¿æ³›ç»†èƒç±»å‹ä¸­æé«˜é€’é€æ•ˆç‡ã€ä¼˜åŒ–ä½“å†…é€’é€é€”å¾„ï¼Œæ˜¯å°†å…¶è½¬åŒ–ä¸ºç ”ç©¶å’Œæ²»ç–—ä¼˜åŠ¿å·¥å…·çš„å…³é”®ã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>RNA editing is a way to diversify, regulate expression, and expand the cell transcriptome. The most common RNA editing is the reversible conversion of adenosine (A) to inosine (I) driven by double-stranded RNA-binding adenosine deaminases (ADARs). As inosine is recognized as guanosine (G) during translation, the RNA editing may result in non-synonymous codon changes. For this reason, ADARs have gained attention as promising enzymes to rewrite mRNA. Many efforts were undertaken to engineer a precise, effective, and controllable ADAR-based system to target certain Adenines on RNA to repair pathological mutations. This review summarizes the advances in ADAR-mediated RNA editing, evolving from systems using antisense oligonucleotides as guide RNA to recruit endogenous or overexpressed ADARs, through more complex setups additionally expressing other RNA-binding proteins, to rational designs harnessing ADARs to convert other nucleotides and amplify the low initial signal. Increasing the specificity and yield of RNA editing, expanding the number of targetable sites, and reducing off-target and bystander activity remain key challenges for these technologies. Improving delivery efficiency across a broad range of cell types, as well as optimizing delivery routes in in vivo studies are also critical to harness them as advantageous tools for both research and therapy.</p>
  </details>
</article>

<article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">Nucleic acids research</span>
      <span class="date">2026-02-24</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 65/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/41755633/" target="_blank">A novel Dual-guide CRISPR-Cas13 strategy improves specificity for single-nucleotide variant detection.</a>
  </h3>
  <p class="title-zh">ä¸€ç§æ–°å‹åŒå¼•å¯¼CRISPR-Cas13ç­–ç•¥æé«˜å•æ ¸è‹·é…¸å˜å¼‚æ£€æµ‹çš„ç‰¹å¼‚æ€§</p>
  <p class="authors">Aguilar-GonzÃ¡lez A, Martos-Jamai I, Ramos-HernÃ¡ndez I, Molina-EstÃ©vez FJ, Villao NV, Puig-Serra P, RodrÃ­guez-Perales S, Torres R</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> RNAæ£€æµ‹ä¸è¯Šæ–­å¹³å°ï¼ˆåŸºäºCRISPR-Cas13çš„åˆ†å­è¯Šæ–­å·¥å…·ï¼‰</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> è¯¥å·¥å…·çš„æ ¸å¿ƒè®¾è®¡æ˜¯æ„å»ºäº†ä¸€ä¸ªåŒå¼•å¯¼RNAç³»ç»Ÿï¼Œé€šè¿‡ä½¿ç”¨ä¸¤ç§ä¸åŒçš„RNAï¼ˆdcrRNAå’ŒdtracrRNAï¼‰ååŒè¯†åˆ«ç›®æ ‡RNAã€‚è¿™ç§è®¾è®¡åˆ©ç”¨ä¸¤ä¸ªç‹¬ç«‹çš„å¼•å¯¼RNAå…±åŒä½œç”¨ï¼Œæé«˜äº†å¯¹ç›®æ ‡åºåˆ—çš„è¯†åˆ«ç²¾åº¦ï¼Œä»è€Œå¢å¼ºäº†å¯¹å•æ ¸è‹·é…¸é”™é…çš„åŒºåˆ†èƒ½åŠ›ï¼Œå‡å°‘äº†è„±é¶æ•ˆåº”ã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. é«˜ç‰¹å¼‚æ€§RNAæ£€æµ‹ï¼šèƒ½å¤Ÿç²¾ç¡®æ£€æµ‹ç‰¹å®šRNAåºåˆ—ï¼Œå¦‚ç—…æ¯’RNAï¼ˆå¦‚SARS-CoV-2ï¼‰ã€‚
2. å•æ ¸è‹·é…¸å˜å¼‚é‰´åˆ«ï¼šå¯åŒºåˆ†é«˜åº¦ç›¸ä¼¼çš„åºåˆ—å˜å¼‚ï¼Œä¾‹å¦‚KRASåŸºå› çš„G12Då’ŒG12Cçªå˜ã€‚
3. ç—…åŸä½“åˆ†å‹ï¼šèƒ½å¤Ÿé‰´åˆ«å¯†åˆ‡ç›¸å…³çš„ç—…åŸä½“åºåˆ—ï¼Œå¦‚åŒºåˆ†çš®è‚¤åˆ©ä»€æ›¼åŸè™«ä¸é»è†œçš®è‚¤åˆ©ä»€æ›¼åŸè™«ã€‚
4. åˆ†å­è¯Šæ–­ï¼šä¸ºä¸‹ä¸€ä»£å¿«é€Ÿã€å¯é çš„ä¸´åºŠåˆ†å­è¯Šæ–­å’Œç²¾å‡†RNAé¶å‘è°ƒæ§æä¾›é€šç”¨å¹³å°ã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> ä½“å¤–å®éªŒè¯å®ï¼Œè¯¥ç³»ç»Ÿä¿æŒäº†å¼ºå¤§çš„é¡ºå¼å’Œåå¼RNaseæ´»æ€§ï¼Œå®ç°äº†é«˜æ•ˆä¸”ç‰¹å¼‚çš„åˆ‡å‰²ã€‚åœ¨åˆ†ææ£€æµ‹ä¸­ï¼Œå®ƒæˆåŠŸæ£€æµ‹äº†SARS-CoV-2 RNAï¼Œå‡†ç¡®åŒºåˆ†äº†KRASçªå˜ï¼Œå¹¶é‰´åˆ«äº†åˆ©ä»€æ›¼åŸè™«äºšå‹ï¼›ä¸´åºŠéªŒè¯è¿›ä¸€æ­¥ç¡®è®¤äº†å…¶å¯¹é˜³æ€§å’Œé˜´æ€§æ ·æœ¬çš„å‡†ç¡®æ£€æµ‹èƒ½åŠ›ï¼Œåœ¨ä¿æŒä¸´åºŠç›¸å…³çµæ•åº¦çš„åŒæ—¶æ˜¾è‘—æé«˜äº†ç‰¹å¼‚æ€§ã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>The emergence of CRISPR-Cas systems has transformed nucleic acid detection and manipulation. Cas13, a type VI CRISPR effector, targets RNA with high sensitivity through both cis (target RNA) and trans (collateral RNA) cleavage. This property enables the use of fluorescent reporters for sensitive diagnostics. However, Cas13's heightened sensitivity also leads to reduced specificity due to its susceptibility to single-nucleotide mismatches, potentially causing off-target effects. To overcome this limitation, we developed the first Dual-guide RNA system for Cas13 that improves mismatch discrimination and enhances target specificity. This system employs two distinct RNAs-dcrRNA and dtracrRNA-which cooperatively recognize the target and reduce off-target activity. In vitro experiments demonstrated robust cis- and trans-RNase activity, indicating efficient and specific cleavage. The system accurately detected SARS-CoV-2 RNA, distinguished KRAS G12D and G12C mutations, and differentiated mucocutaneous from cutaneous Leishmania sequences in analytical assays, with clinical validation confirming accurate detection of positive and negative samples. These results highlight the Dual-guide Cas13 platform's potential for precise, rapid, and reliable RNA detection. Overall, this approach represents a substantial advance over conventional Cas13 systems, offering improved specificity while maintaining clinically relevant sensitivity, and provides a generalizable tool for next-generation molecular diagnostics and precision RNA targeting and regulation.</p>
  </details>
</article>

<article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">MedComm</span>
      <span class="date">2026-03-01</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 45/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/41756253/" target="_blank">RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets.</a>
  </h3>
  <p class="title-zh">RNAè°ƒæ§ç½‘ç»œï¼šç™Œç—‡å…¨æ™¯ä¸­çš„å…³é”®æ¢çº½ä¸æ–°å…´æ²»ç–—é¶ç‚¹</p>
  <p class="authors">Yin X, Du Z, Jiang S, Liao Y, Wang C, Li J, Zhang H, Wei TT</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> ç»¼è¿°è®ºæ–‡ï¼ˆéå•ä¸€å·¥å…·ï¼Œè€Œæ˜¯å¯¹å¤šç§RNAé¶å‘å¹²é¢„ç­–ç•¥çš„è¯„ä¼°ï¼ŒåŒ…æ‹¬åä¹‰å¯¡æ ¸è‹·é…¸ã€RNAé€‚é…ä½“ã€CRISPR-Cas13ç³»ç»Ÿç­‰ï¼‰</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> æœ¬æ–‡å¹¶éä»‹ç»å•ä¸€å·¥ç¨‹è®¾è®¡ï¼Œè€Œæ˜¯ä»ç³»ç»Ÿç”Ÿç‰©å­¦è§’åº¦ï¼Œç»¼è¿°äº†RNAè°ƒæ§ç½‘ç»œï¼ˆç”±mRNAã€miRNAã€lncRNAã€circRNAç­‰æ„æˆï¼‰é€šè¿‡ç«äº‰æ€§å†…æºRNAæµ·ç»µæ•ˆåº”ã€RNA-è›‹ç™½è´¨å¤åˆç‰©ç»„è£…ã€RNAç¼–è¾‘ï¼ˆå¦‚A-to-Iç¼–è¾‘ã€m6Aä¿®é¥°ï¼‰ç­‰å¤šç§æœºåˆ¶ï¼Œåœ¨å¤šç»´åº¦é‡å¡‘åŸºå› è¡¨è¾¾ç¨‹åºçš„æ•´ä½“æ€è·¯ã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. è§£ç ç™Œç—‡ç”Ÿç‰©å­¦ï¼šé˜æ˜RNAç½‘ç»œåœ¨è‚¿ç˜¤ä»£è°¢é‡ç¼–ç¨‹ã€è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒå¡‘é€ å’Œç™Œç—‡å¹²ç»†èƒç‰¹æ€§ç»´æŒä¸­çš„åŠŸèƒ½ã€‚
2. ä½œä¸ºè¯Šæ–­ç”Ÿç‰©æ ‡å¿—ç‰©ï¼šä¾‹å¦‚ä½œä¸ºæ¶²ä½“æ´»æ£€çš„é¶æ ‡ã€‚
3. ä½œä¸ºæ²»ç–—å¹²é¢„é¶ç‚¹ï¼šè¯„ä¼°äº†ä»¥RNAç½‘ç»œä¸ºé¶ç‚¹çš„å¤šç§å¹²é¢„ç­–ç•¥ï¼ˆå¦‚åä¹‰å¯¡æ ¸è‹·é…¸ã€RNAé€‚é…ä½“ã€CRISPR-Cas13ç³»ç»Ÿï¼‰åœ¨ç™Œç—‡ç²¾å‡†æ²»ç–—ä¸­çš„åº”ç”¨æ½œåŠ›ã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> æœ¬æ–‡æ˜¯ä¸€ç¯‡ç»¼è¿°ï¼ŒæœªæŠ¥å‘Šå…·ä½“çš„å®éªŒæ•°æ®ã€‚å…¶æ ¸å¿ƒç»“è®ºæ˜¯ï¼šRNAè°ƒæ§ç½‘ç»œå› å…¶åŠ¨æ€å¯è°ƒçš„ç‰¹æ€§ï¼Œå·²æˆä¸ºæå…·å‰æ™¯çš„ç²¾å‡†åŒ»å­¦å¹²é¢„èŠ‚ç‚¹ï¼Œä½†å¤§å¤šæ•°ç›¸å…³çš„RNAé¶å‘ç–—æ³•ï¼ˆå¦‚åŸºäºCas13çš„ç³»ç»Ÿï¼‰ç›®å‰ä»å¤„äºä¸´åºŠå‰ç ”ç©¶é˜¶æ®µï¼Œé¢ä¸´ä¸´åºŠè½¬åŒ–çš„ç“¶é¢ˆã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>Cancer is a global health challenge. The initiation and progression of cancer are correlated with dynamic dysregulation of RNA regulatory networks. This review systematically explains how contending RNAs (including mRNA, miRNA, lncRNA, circRNA, etc.) remold gene expression programs across multiple dimensions. They do this primarily through the competing endogenous RNA sponge effect, RNA-protein complex assembly, RNA editing (A-to-I editing, m6A modification, etc.), tumorigenesis, heterogeneous evolution, and therapeutic resistance. RNA regulatory networks do not only help one to decode cancer biology but because they are dynamic in nature, they are now also being looked at as good precision targets for diagnosis and treatment. This article integrates recent findings on the emerging functions of RNA networks in tumor metabolic reprogramming, tumor immune microenvironment shaping, and cancer stem cell property maintenance, while highlighting their clinical application prospects as liquid biopsy biomarkers. Our therapies focus on assessing the potential and clinical translation bottlenecks of novel RNA-targeted interventions, including antisense oligonucleotides, RNA aptamers, and the CRISPR-Cas13 system. A dynamic adjustability made the RNA-targeted therapies promising intervention nodes in precision medicine even if most of them are still in a preclinical state.</p>
  </details>
</article>

<article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">bioRxiv : the preprint server for biology</span>
      <span class="date">2026-02-20</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 45/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/41757025/" target="_blank">Mechanistic machine learning enables interpretable and generalizable prediction of prime editing outcomes.</a>
  </h3>
  <p class="title-zh">æœºåˆ¶æ€§æœºå™¨å­¦ä¹ å®ç°å¯è§£é‡Šä¸”å¯æ³›åŒ–çš„å…ˆå¯¼ç¼–è¾‘ç»“æœé¢„æµ‹</p>
  <p class="authors">Hsu A, Chen PJ, Li AH, Hemez CF, Gao XD, Terrey M, Nelson C, Selvam V</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> æœºå™¨å­¦ä¹ é¢„æµ‹æ¨¡å‹/å…ˆå¯¼ç¼–è¾‘ï¼ˆPEï¼‰ä¼˜åŒ–å¹³å°</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> è¯¥å·¥å…·ï¼ˆOptiPrimeï¼‰çš„æ ¸å¿ƒè®¾è®¡æ€è·¯æ˜¯ï¼š1ï¼‰åŸºäºå½“å‰å¯¹å…ˆå¯¼ç¼–è¾‘ï¼ˆPrime Editingï¼‰åˆ†å­æœºåˆ¶çš„ç†è§£ï¼Œæ„å»ºä¸€ä¸ªæœºåˆ¶é©±åŠ¨çš„æœºå™¨å­¦ä¹ æ¨¡å‹ã€‚2ï¼‰å°†ç¼–è¾‘æ•ˆç‡é¢„æµ‹ä¸å¯¹å“ºä¹³åŠ¨ç‰©é”™é…ä¿®å¤ï¼ˆMMRï¼‰æœºåˆ¶çš„å­¦ä¹ ç›¸ç»“åˆï¼Œä½¿æ¨¡å‹ä¸ä»…èƒ½é¢„æµ‹ç»“æœï¼Œè¿˜èƒ½ç†è§£èƒŒåçš„ç”Ÿç‰©å­¦å†³å®šå› ç´ ã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. **é¢„æµ‹ç¼–è¾‘æ•ˆç‡**ï¼šé«˜ç²¾åº¦é¢„æµ‹å…ˆå¯¼ç¼–è¾‘å‘å¯¼RNAï¼ˆpegRNAï¼‰çš„ç¼–è¾‘æ•ˆç‡ã€‚2. **é¢„æµ‹å¤æ‚ç¼–è¾‘ç­–ç•¥ç»“æœ**ï¼šå¯æ‰©å±•åº”ç”¨äºé¢„æµ‹åˆ‡å£å‘å¯¼RNAï¼ˆPE3ï¼‰å’ŒåŒpegRNAï¼ˆtwinPEï¼‰ç­–ç•¥çš„ç¼–è¾‘ç»“æœã€‚3. **ä¼˜åŒ–ç¼–è¾‘è®¾è®¡**ï¼šé€šè¿‡è¯†åˆ«å†³å®šMMRçš„å› å­ï¼Œèƒ½å¤Ÿæ¨èå¯é€ƒé¿MMRçš„â€œæ²‰é»˜ç¼–è¾‘â€ä½ç‚¹ï¼Œä»è€Œä¼˜åŒ–pegRNAè®¾è®¡ä»¥æé«˜ç¼–è¾‘æ•ˆç‡ã€‚4. **è¾…åŠ©æ²»ç–—æ€§åº”ç”¨**ï¼šç”¨äºåœ¨å„ç§å‰ç»æ€§æ²»ç–—åœºæ™¯ï¼ˆåŒ…æ‹¬åŸä»£äººç±»å’Œå°é¼ ç»†èƒï¼‰ä¸­é«˜æ•ˆè®¾è®¡ç¼–è¾‘æ–¹æ¡ˆã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> 1. **é¢„æµ‹æ€§èƒ½ä¼˜å¼‚**ï¼šOptiPrimeåœ¨å…ˆå¯¼ç¼–è¾‘æ•ˆç‡é¢„æµ‹ä¸Šè¾¾åˆ°äº†æœ€å…ˆè¿›çš„å‡†ç¡®åº¦ã€‚2. **æœºåˆ¶ç†è§£éªŒè¯**ï¼šéªŒè¯äº†æ¨¡å‹ç¡®å®å­¦ä¹ åˆ°äº†å“ºä¹³åŠ¨ç‰©é”™é…ä¿®å¤ï¼ˆMMRï¼‰çš„å…³é”®å†³å®šå› ç´ ï¼Œå…¶æ¨èçš„â€œæ²‰é»˜ç¼–è¾‘â€èƒ½æœ‰æ•ˆæé«˜PEæ•ˆç‡ã€‚3. **åº”ç”¨éªŒè¯å¹¿æ³›**ï¼šåœ¨å¤šç§ç»†èƒç±»å‹ï¼ˆåŒ…æ‹¬åŸä»£äººç±»å’Œå°é¼ ç»†èƒï¼‰å’Œæ²»ç–—ç›¸å…³èƒŒæ™¯ä¸‹æˆåŠŸéªŒè¯äº†å…¶é¢„æµ‹å’Œä¼˜åŒ–èƒ½åŠ›ï¼Œå®ç°äº†é«˜åº¦ç®€åŒ–å’Œé«˜æ•ˆçš„ç¼–è¾‘æ–¹æ¡ˆè®¾è®¡ã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>Although prime editing (PE) can effect virtually any specified local change to genomic DNA in living systems, its efficient application currently requires extensive optimization of prime editing guide RNA (pegRNA) sequences. We present OptiPrime, a machine learning model of PE efficiency based on our current understanding of the mechanism of prime editing. OptiPrime achieves state-of-the-art accuracy on PE efficiency prediction and also enables prediction of nicking guide RNA (PE3) and dual pegRNA (twinPE) outcomes. We validated that OptiPrime has learned the determinants of mammalian mismatch repair (MMR), and is therefore well suited for nominating MMR-evasive silent edits that improve PE efficiency. We demonstrate the utility of OptiPrime in a variety of prospective therapeutic contexts, including in primary human and mouse cells. Finally, we show how OptiPrime can be used to achieve highly streamlined and efficient</p>
  </details>
</article>

<article class="paper-card">
  <div class="paper-header">
    <div class="left">
      <span class="journal">MedComm</span>
      <span class="date">2026-03-01</span>
    </div>
    <span class="score-badge">ç›¸å…³æ€§ 35/100</span>
  </div>
  <h3 class="title">
    <a href="https://pubmed.ncbi.nlm.nih.gov/41756256/" target="_blank">Inhibiting ADAR1-Mediated Excessive Epigenetic A-to-I RNA Editing Improves the Immune Microenvironment and Increases Sensitivity to Immunotherapy in Lung Adenocarcinoma.</a>
  </h3>
  <p class="title-zh">æŠ‘åˆ¶ADAR1ä»‹å¯¼çš„è¿‡åº¦è¡¨è§‚é—ä¼ A-to-I RNAç¼–è¾‘å¯æ”¹å–„è‚ºè…ºç™Œå…ç–«å¾®ç¯å¢ƒå¹¶å¢å¼ºå…ç–«æ²»ç–—æ•æ„Ÿæ€§</p>
  <p class="authors">Wang S, Zheng S, Liu C, Zhang C, Wang X, Wang Z, Wang Y, Feng X</p>
  <div class="summary">
    <div class="summary-block"><strong>å·¥å…·ç±»å‹:</strong> æ²»ç–—ç­–ç•¥/é¶ç‚¹ï¼ˆåŸºäºADAR1æŠ‘åˆ¶çš„RNAç¼–è¾‘è°ƒæ§å·¥å…·ï¼‰</div>
    <div class="summary-block"><strong>è®¾è®¡æ€è·¯:</strong> æœ¬ç ”ç©¶å¹¶éè®¾è®¡ä¸€ä¸ªæ–°çš„å·¥ç¨‹åŒ–ç¼–è¾‘å·¥å…·ï¼Œè€Œæ˜¯å°†å†…æºæ€§ADAR1é…¶åŠå…¶ä»‹å¯¼çš„A-to-I RNAç¼–è¾‘è¿‡ç¨‹æœ¬èº«è§†ä¸ºä¸€ä¸ªå¯è°ƒæ§çš„â€œç³»ç»Ÿâ€ã€‚å…¶æ ¸å¿ƒæ€è·¯æ˜¯ï¼šé€šè¿‡è¯ç†æˆ–é—ä¼ æ‰‹æ®µæŠ‘åˆ¶ADAR1çš„æ´»æ€§ï¼Œä»è€Œç³»ç»Ÿæ€§é™ä½è‚¿ç˜¤ç»†èƒä¸­è¿‡åº¦çš„A-to-Iç¼–è¾‘æ°´å¹³ï¼Œä»¥æ­¤ä½œä¸ºä¸€ç§å¹²é¢„è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒçš„æ²»ç–—ç­–ç•¥ã€‚</div>
    <div class="summary-block"><strong>åŠŸèƒ½ä¸åº”ç”¨:</strong> 1. åŠŸèƒ½ï¼šè°ƒæ§å…¨å±€æ€§ï¼ˆéä½ç‚¹ç‰¹å¼‚æ€§ï¼‰çš„A-to-I RNAç¼–è¾‘æ°´å¹³ã€‚
2. åº”ç”¨ï¼ša) æ”¹å–„è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒï¼ˆå¦‚å¢åŠ PD-L1è¡¨è¾¾ã€å¢å¼ºCD8+ Tç»†èƒæµ¸æ¶¦ï¼‰ï¼›b) å¢å¼ºè‚¿ç˜¤å¯¹å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚æ²»ç–—çš„æ•æ„Ÿæ€§ï¼›c) ä½œä¸ºç ”ç©¶RNAç¼–è¾‘åœ¨ç™Œç—‡å…ç–«ä¸­åŠŸèƒ½çš„æ¢é’ˆæˆ–æ¨¡å‹ã€‚</div>
    <div class="summary-block"><strong>å…³é”®ç»“æœ:</strong> å…³é”®å®éªŒç»“æœè¡¨æ˜ï¼Œåœ¨è‚ºè…ºç™Œå°é¼ æ¨¡å‹ä¸­æŠ‘åˆ¶ADAR1ï¼Œèƒ½æ˜¾è‘—æ”¹å–„è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒï¼ˆè¡¨ç°ä¸ºPD-L1è¡¨è¾¾å¢åŠ å’ŒCD8+ Tç»†èƒæµ¸æ¶¦å¢å¼ºï¼‰ï¼Œå¹¶æœ€ç»ˆæé«˜åŠ¨ç‰©å¯¹å…ç–«æ²»ç–—çš„å“åº”å’Œç”Ÿå­˜è·ç›Šã€‚</div>
  </div>
  <details class="abstract">
    <summary>æŸ¥çœ‹æ‘˜è¦</summary>
    <p>Adenosine-to-inosine (A-to-I) RNA editing, predominantly catalyzed by the enzyme adenosine deaminase acting on RNA 1 (ADAR1), has attracted interest due to its essential functions in regulating immune response and cancer progression. This research investigates ADAR1 inhibition as a promising strategy aimed at improving immunotherapy efficacy in lung adenocarcinoma (LUAD) and explores the underlying mechanisms. Findings from murine models demonstrate that ADAR1 suppression within tumors notably improves the immune microenvironment, marked by increased PD-L1 expression and enhanced CD8</p>
  </details>
</article>
  </main>

  <footer>
    <p>æ•°æ®æ¥æº: <a href="https://pubmed.ncbi.nlm.nih.gov/" target="_blank">PubMed</a></p>
    <p>AI æ’åº/æ€»ç»“: DeepSeek</p>
  </footer>
</body>
</html>
